FORMULATING FOR MILDNESS 61 120 100 80 60 61 40 20 0
Positive CTL
Untreated RHE
Negative CTL
0.5%
OceanMist CL
1.5%
OceanMist CL
Atopic RHE 3% OceanMist (Atopic RHE)
Figure 7: FLG abundance after treatment of Atopic RHE with Natura-Tec Marine OceanMist CL during 48h.
Molecules generated by the immune system, cytokines, are polypeptides produced in response to different stimuli. They are involved in the regulation of immune functions.
The study is divided in 2 distinct parts: 1. Morphology analysis of RHE/Th2
treated with the new active by histology and haematoxylin/eosin (H/E) staining to assess the capacity of the new active to restore the barrier function.
As expected, RHE stimulated by Th2 cytokines presents alteration of morphology, pyknotic nuclei, œdema and impaired barrier (Fig 5). With 3% of use,
120 100 80 60 40 43 20 0
Positive CTL
Untreated RHE
Negative CTL
0.5%
OceanMist CL
1.5%
OceanMist CL
Atopic RHE 3% OceanMist (Atopic RHE)
Figure 9: INV abundance after treatment of Atopic RHE with Natura-Tec Marine OceanMist CL during 48h.
April 2020 5% OceanMist (Atopic RHE)
Figure 10: Analysis by immunofluorescence of INV abundance after treatment of Atopic RHE with Natura-Tec Marine OceanMist CL during 48H.
PERSONAL CARE EUROPE 3%
OceanMist CL
5%
OceanMist CL
38 31 100 70 Control untreated (Normal RHE) RHE/Th2 (Atopic RHE) -62% 101 5% OceanMist (Atopic RHE)
Figure 8: Analysis by immunofluorescence of FLG abundance after treatment of Atopic RHE with Natura-Tec Marine OceanMist CL during 48H.
the new active drastically reduces numbers of pyknotic nuclei by protecting cells from abnormal deterioration. The new active repairs skin barrier and reduces typical œdema of AS.
The new active counteracts the negative effects of inflammatory responses, reduces skin alterations of AS, promoting skin health conditions. 2. Analysis by immunofluorescence of
the effects of the new active on the protein abundance of filaggrin (FLG), involucrin (INV) and carbonic anhydrase 2 (CA2) from RHE/Th2 (Atopic RHE) treated during 48h.
+169%
l Carbonic anhydrase II (CA2) abundance In the pictures obtained by fluorescent microscopy (Fig 6), we can see that in normal skin (control untreated) the level of CA2 is very low (no green fluorescence) and in AS (RHE stimulated by Th2 cytokines), CA2 is largely increased (strong green fluorescence). We demonstrated that after 48H of
treatment, 3% of the new active reduces carbonic anhydrase levels in AS by 38,7%. By reducing the level of CA2, the new active helps to fight the effects of inflammatory syndrome in restoring the parameters of a normal kin.
3%
OceanMist CL
5%
OceanMist CL
46 46 72 Control untreated (Normal RHE) RHE/Th2 (Atopic RHE) 100 79 -54% +72%
INV abundance (% vs Untreated CTL)
FLG abundance (% vs untreated CTL)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
